Photobiomodulation for non-exudative age-related macular degeneration
CONCLUSIONS: Currently there remains uncertainty whether PBM treatment is beneficial in slowing progression of non-exudative macular degeneration. There is a need for further well-designed controlled trials assessing dosimetry, powered for both effectiveness and safety outcomes. Consideration should be given to the adoption of agreed clinical outcome measures and patient-based outcome measures for AMD.PMID:34097768 | DOI:10.1002/14651858.CD013029.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Christin Henein David Hw Steel Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Blindness | Canada Health | Clinical Trials | Databases & Libraries | Eyes | General Medicine | Mitochondrial Disease | Opthalmology | Study | Vitamin A